BioMedNewsBreaks

FridayApr 21, 2023 9:40 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Registered Direct Offering Expected to Total $1.9M

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has entered into a definitive agreement. The company announced a registered direct offering totaling $1.9 million; the agreement is with a single healthcare-focused institutional investor and includes the purchase and sale of 1,585,350 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.22 per share (or common stock equivalents in lieu thereof). According to the announcement, a concurrent private placement calls for the company to also issue unregistered warrants to purchase up to 3,170,700…

Continue Reading

ThursdayApr 20, 2023 10:20 am

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Inks Asset Purchase Agreement for 50% Ownership of Global Response Aid

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed an asset purchase agreement with Cellvera Ltd. According to the announcement, the agreement gives Aditxt a 50% ownership in G Response Aid FZE; the remaining 50% ownership belongs to global logistics leader Agility Inc. Calling the agreement a “significant step” for the company, Aditxt officials noted that the agreement allows the company to partner with Agility to address a growing global market need for effective antivirals. Specifics of the transaction include the consideration of (A) $24.5 million, comprised of: (i)…

Continue Reading

WednesdayApr 19, 2023 11:40 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Featured in Equity Research Report

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in an equity research report published by Aegis Capital Corp. In the report, Aegis Capital maintained a buy rating for BVXV at a $70 target price. The publication reads, “R&D expenses for 2022 of $5.8 million were in-line with our expectations and G&A expenses were a bit higher than estimated at $5.3 million. We believe R&D expenses could rise to $7 million in 2023 as the company licenses additional NanoAb candidates and assuming that…

Continue Reading

TuesdayApr 18, 2023 12:27 pm

BioMedNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Announces Participation in Upcoming Planet MicroCap Showcase

IGC Pharma (NYSE American: IGC) will be presenting at this month’s Planet MicroCap Showcase: VEGAS 2023; the event is slated for Wednesday, April 26, 2023, at 7:30 p.m. ET. According to the announcement, IGC Pharma CEO Ram Mukunda and principal financial officer Claudia Grimaldi will be hosting the presentation; the session will include time for questions and answers. The live presentation will be available via webcast; a replay of the presentation will be available on the conference event platform. In addition, Mukunda and Grimaldi will be available for one-on-one, in-person meetings, to be held at the conference venue in Las…

Continue Reading

TuesdayApr 18, 2023 11:38 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Reports FY 2022 Financial Statements, Corporate Update

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, published its full-year financial results for the year ended December 31, 2022; the report also included key business updates. Highlights of the report include the signing of definitive agreements with the Max Planck Society (“MPG”) and the University Medical Center Göttingen, Germany (“UMG”) designed to enable BiondVax to build a pipeline of “bio-better” nanosized VHH antibodies (NanoAbs); notice that the unique physicochemical characteristics of NanoAbs being generated by BiondVax’s scientific partners show several competitive attributes,…

Continue Reading

MondayApr 17, 2023 1:09 pm

BioMedNewsBreaks – Progressive Care Inc. (RXMD) Identified as a High-Growth Opportunity

Progressive Care (OTCQB: RXMD) offers services and technology that supports the managed health care industry to reduce costs and improve the quality of care. “The company has been steadily building both its pharmacy and data-management divisions as revenues continue to improve. However, a couple of extremely revealing events recently transpired that may have set the course for considerable upside potential. “The first inkling of something big cooking was revealed in a September press release, which announced that Progressive Care had successfully completed a recapitalization of its debt as well as a strategic investment of $6 million from NextPlat Corp (NASDAQ:…

Continue Reading

MondayApr 17, 2023 12:40 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Completes Critical Step in Advancing Lucid-MS Pipeline

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced completion of the first-in-human (“FIH”) sentinel dosing of Lucid-21-302 (“Lucid-MS”) in its phase I clinical trial evaluating its novel drug candidate as an orally administered treatment for multiple sclerosis (“MS”). “Dosing the sentinel subject is a major achievement for our team and culmination of more than a decade of very promising research by a seasoned development team passionate about changing the future treatment…

Continue Reading

MondayApr 17, 2023 12:32 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Releases Shareholder Update on Major Programs, M&A Plans

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. The company was chosen as a backup bidder. Despite an objection filed by Aditxt noting issues related to fairness and good faith, Pearsanta remains the backup bidder. Earlier this month, Aditxt formed a wholly owned subsidiary, Adivir Inc.,…

Continue Reading

FridayApr 14, 2023 11:30 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Innovative NanoAb Pipeline to Disrupt High-Value Market Opportunities

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. “In many compelling ways, BiondVax punches well above its weight compared to biopharma companies of similar market cap: BiondVax gained extensive drug development expertise [through previous clinical trials evaluating the M-001 universal influenza vaccine candidate], which is expected to be invaluable in the development and commercialization of the NanoAb pipeline. The company plans to undertake the first-in-human phase 1/2a clinical trial evaluating its inhaled anti-COVID-19 NanoAb therapy later this year. This rapid development path hinges…

Continue Reading

WednesdayApr 12, 2023 2:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Provides Update on Spin-Out Plan, Announces Shareholder Meeting

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, plans to complete its spin-out transaction outlined in a plan of arrangement. The plan called for shares of the yet-to-be-formed wholly owned subsidiary to be separated into an independent public company. According to the announcement, the transaction is slated to be complete in July 2023 and is designed to enable FSD Pharma to focus on developing core assets and maximizing shareholder value. The company noted that, as of…

Continue Reading